GERD (acid reflux) Board decisions

The Board granted service connection for GERD, and remanded the other issues for further development.

The appeal for service connection for GERD was dismissed as the Veteran withdrew his appeal in February 2025.

The Board granted an initial rating of 30 percent for gastroesophageal reflux disease, finding that the Veteran's symptoms met the criteria for a considerable impairment of health.

The Board granted an initial 30 percent rating for gastroesophageal reflux disease (GERD) and remanded the claim for a higher rating.

The Board remands the claims for further development of medical opinion evidence regarding the etiology and aggravation of the Veteran's helicobacter pylori and GERD due to his service-connected musculoskeletal disabilities.

The Board denied service connection for gastroesophageal reflux disease (GERD) and obstructive sleep apnea (OSA) as they were not incurred in or otherwise caused by the Veteran's military service.

The Board denied a rating in excess of 30 percent for both migraine headaches and a disability characterized by GERD and IBS, as the evidence did not support higher ratings.

The Board denied an initial compensable disability rating for hypertension and remanded the claims for service connection for emphysema and an esophageal condition due to a pre-decisional error in not providing required examinations under the PACT Act.

The Board denied an initial rating in excess of 60 percent for GERD, as the Veteran's symptoms did not meet the criteria for a higher rating under the applicable diagnostic codes.

The Board granted service connection for migraines and GERD, as secondary to the Veteran's service-connected tinnitus and scars, respectively. The appeal was remanded for further development regarding a claim of service connection for allergies.

The appeal for an increased rating for service-connected GERD was dismissed due to the Board already addressing the matter on appeal under a different docket number.

The Board denied service connection for type II diabetes and denied increased ratings for various disabilities, including degenerative joint disease of the lumbar spine, radiculopathy, hiatal hernia with GERD, status post bilateral inguinal hernia repair, bilateral hearing loss, and other specified trauma and stressor related disorder.

The Board remands the case to schedule an examination for a more accurate assessment of the Veteran's GERD symptoms, excluding the ameliorative effects of medication.

The Veteran's service connection for an acquired psychiatric disorder, diagnosed as major depressive disorder and also claimed as severe recurrent major depression without psychotic features was granted. A rating of 30 percent, but not higher, for gastroesophageal reflux disease (GERD) from November 21, 2020, was granted.

The Board granted service connection for GERD and an acquired psychiatric disorder, both found to be secondary to the Veteran's service-connected conditions.

The Board granted service connection for gastroesophageal reflux disease (GERD) as secondary to a service-connected cervical spine disability, and directly established service connection for allergic rhinitis and sinusitis.

The Board denied the Veteran's claims for compensation under 38 U.S.C. § 1151 for various disabilities, including a right shoulder disability and conditions secondary to it, as there was no evidence that VA treatment caused additional disability beyond what would have occurred due to pre-existing conditions.

The Board granted service connection for an acquired psychiatric disorder, other than PTSD, diagnosed as an unspecified depressive disorder, and denied a compensable rating for allergic rhinitis and a rating in excess of 10 percent for GERD with hiatal hernia.

The Board granted a 30 percent evaluation for GERD and a 50 percent evaluation for cluster headaches, but denied an increased rating for right foot plantar fasciitis. The Veteran was also granted a 10 percent evaluation for external hemorrhoids effective May 19, 2024.

The Board granted an increased rating of 30 percent for gastroesophageal reflux disease (GERD), effective June 1, 2017.